Brain Scientific Inc. (BRSF) Provides Affordable Solutions for COVID Studies

• Researchers struggle to understand the immediate effects of COVID, with no clear census on the long-term neurological impact
• COVID-19 has shown itself to be unique in how it interacts with the brain
• Brain e-tattoos implanted in forehead will be next wave of innovation for neurology

Brain Scientific (OTCQB: BRSF) is meeting the growing need for improved brain monitoring with cost-efficient, disposable, and portable cutting-edge technology. This last year has seen an increased demand for disposable neurological technology accessible to all, adaptable for widespread use, and that provides quick, reliable information on the patient’s condition.

As the pandemic winds down, thanks to dedicated medical workers, social-distancing, mask-wearing and new vaccines, there are still many questions that need to be addressed.

The scientific world is only at the beginning of truly understanding the effects of COVID-19 on the brain. A year into the pandemic, researchers struggle to understand the immediate effects, with no clear census on the long-term impact. Neurological symptoms may go well beyond a loss of taste and smell or “brain fog” to problems with attention, concentration, and multitasking. The question is, how long will these symptoms last, and will patients eventually recover.

The Global Council on Brain Health (“GCBH”) has stated that critical research is needed in assessing how COVID-19 impacts later-in-life cognitive decline or dementia. It is not just the virus that needs to be studied, but also the impact of isolation during the pandemic on older adult brains.

COVID-19 has shown itself to be unique in how it interacts with the brain. Megakaryocytes, cells that produce platelets and primarily reside in bone marrow, have been found in the autopsied brains of COVID victims. This phenomenon has never been seen before. It may block blood flow to the brain and thereby be responsible for brain fog.

Figuring out why some patients are unaffected cognitively from COVID while others are left with significant and possibly long-term effects is essential in understanding this virus. More monitoring is needed to find the answers. That’s where Brain Scientific’s cutting-edge technology comes into play.

The NeuroEEG(TM) device is a portable, wireless, and compact device that acquires, records, transmits, and displays the wearer’s electrical brain activity. This device works in conjunction with the NeuroCap(TM), a hospital-grade disposable EEG headset featuring 19 active channels and 22 electrodes that comes in sizes for adults and pediatric patients. These devices are portable, making it simpler to take the needed tech to the patient rather than bringing the patient to the equipment.

The company is working on development of Brain E-Tattoo(TM) that in the future will provide access to long-term studies and inroads in helping identify root neurological problems. This tiny device will use graphene-based electrodes connected to the micro EEG clipped behind the ear that then transfers data to a cloud application. The data will be continuously analysed by artificial intelligence, which provides 24/7 uninterrupted monitoring.

“COVID-19 put a spotlight on the outdated and inefficient EEG testing protocols,” said Boris Goldstein, BRSF co-founder and executive. “Disposable technology made a significant impact to ensure brain scans could occur safely during the pandemic. Now, brain e-tattoos implanted in the forehead will be the next wave of innovation for neurology. The advancement will allow for long-term monitoring capabilities and uninterrupted data collection from patients with neurological conditions. Clinicians will be able to identify brain wave activity beyond the clinical setting with no impact to the patient’s daily life.”

Thanks to cutting-edge technology such as BRSF’s NeuroCap, NeuroEEG and e-Tattoo, the answers may just lie right around the corner.

For more information, visit the company’s website at www.BrainScientific.com/Invest-Now.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.